Table 1

Baseline characteristics: demographics, patient information and education, and type of follow-up

Control group (n=63)Intervention group (n=64)
n*n*
Female, n (%)6344 (69.8)6440 (62.5)
Age, mean (SD), years6345.4 (13.0)6448.6 (12.6)
Professional activity6062
 Currently employed46 (76.7)35 (56.5)
 Retired8 (13.3)11 (17.7)
 On sick leave/disability6 (10.0)16 (25.8)
Socioprofessional status (SPS), n (%)6164
 Higher SPS21 (34.4)25 (39.1)
 Lower SPS36 (59.0)36 (56.3)
 Other4 (6.6)3 (4.7)
Size of place of residence (inhabitants), n (%)6263
 ≥200 0009 (14.5)14 (22.2)
 10 000–199 99916 (25.8)18 (28.6)
 <10 00037 (59.7)31 (49.2)
Education level, n (%)6264
 High school or less27 (43.5)32 (50.0)
 University35 (56.5)32 (50.0)
Family status, n (%)6264
 Living alone or single12 (19.4)10 (15.6)
 Living with family/in a couple or family relationship50 (80.6)54 (84.4)
Current tobacco consumption, n (%)6213 (21.0)6425 (39.1)
Usual care follow-up, n (%)6364
 Only by rheumatologist in hospital23 (36.5)25 (39.1)
 Only by rheumatologist in private practice17 (27.0)21 (32.8)
 Both in hospital and private practice23 (36.5)18 (28.1)
Self-reported patients’ information about the disease† (0–10), median (IQR)628.0 (6.0–9.0)638.0 (6.0–9.0)
Self-reported patients’ information about treatment (including bDMARDs)† (0–10), median (IQR)627.0 (5.0–8.0)637.0 (6.0–9.0)
Patients’ information sources about disease or treatments, n (%)
 General practitioner6141 (67.2)6137 (60.7)
 Rheumatologist in private care6136 (59.0)6039 (65.0)
 Rheumatologist in hospital6255 (88.7)6256 (90.3)
 Face-to-face generic patient education616 (9.8)568 (14.3)
 Group patient education601 (1.7)564 (7.1)
 Nurse6219 (30.6)5922 (37.3)
 Pharmacist619 (14.8)5813 (22.4)
 Physiotherapist6116 (26.2)6011 (18.3)
 Other health practitioner601 (1.7)575 (8.8)
 Relatives6016 (26.7)5617 (30.4)
 Patient association605 (8.3)566 (10.7)
 Internet6241 (66.1)6044 (73.3)
 Brochures or leaflets6239 (62.9)5832 (55.2)
 Books625 (8.1)554 (7.3)
 Television617 (11.5)5712 (21.1)
 Other563 (5.4)512 (3.9)
Information given by the patient’s doctor about bDMARDs (yes), n (%)6237 (59.7)6239 (62.9)
  • *Number of available data.

  • †High score indicates better score.

  • bDMARDs, biological disease-modifying antirheumatic drugs.